An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

This study has been completed.
Merck A.E., Greece
Information provided by (Responsible Party):
Merck KGaA Identifier:
First received: April 26, 2010
Last updated: July 15, 2014
Last verified: July 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2012
  Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)